Eurofins Scientific announced it has signed an agreement to acquire GATC Biotech AG, one of Europe’s specialists in DNA sequencing. The transaction is expected to close in July, subject to the fulfilment of customary closing conditions.
Founded in 1990, GATC has achieved a strong recognition for DNA and RNA sequencing, as well as bioinformatics in Europe. GATC has built a reputation for innovative, internally-developed applications, as well as industry-leading turn-around time. The acquisition should therefore further reinforce Eurofins' footprint in DNA sequencing, and strengthen the Group's technological platform supporting its genetic testing innovations.
“We are excited to be joining the Eurofins family of laboratories and look forward to the next phase of our development within the Group,” Peter Pohl, CEO and Co-founder of GATC said. “We are confident that with access to Eurofins’ global network and technical competencies, we should be able to expand our analytical portfolio and services to benefit all our existing and future clients.”
“We look forward to providing GATC access to the complete capabilities of the Eurofins Group,” Dr. Gilles Martin, Eurofins CEO said. “This transaction is a demonstration of Eurofins' commitment to genomics services. We believe that advances in gene sequencing will continue to drive innovations not only in clinical diagnostics, but in the broader bioanalytical testing market as well."